Literature DB >> 33565577

Correlation of hepcidin and serum ferritin levels in thalassemia patients at Chiang Mai University Hospital.

Adisak Tantiworawit1, Sujaree Khemakapasiddhi1, Thanawat Rattanathammethee1, Sasinee Hantrakool1, Chatree Chai-Adisaksopha1, Ekarat Rattarittamrong1, Lalita Norasetthada1, Pimlak Charoenkwan2, Somdet Srichairatanakool3, Kanda Fanhchaksai2.   

Abstract

Hepcidin is a key iron-regulatory hormone, the production of which is controlled by iron stores, inflammation, hypoxia and erythropoiesis. The regulation of iron by hepcidin is of clinical importance in thalassemia patients in which anemia occurs along with iron overload. The present study aimed to evaluate the correlation between serum hepcidin and ferritin levels in thalassemia patients. This cross-sectional study investigated 64 patients with thalassemia; 16 β-thalassemia major (BTM), 31 β-thalassemia/hemoglobin (Hb) E (BE), and 17 Hb H + AE Bart's disease (Hb H + AE Bart's). The levels of serum hepcidin and ferritin, and Hb of the three groups were measured. The median values of serum ferritin and Hb were significantly different among the three groups, whereas serum hepcidin values were not observed to be significantly different. The correlation of the serum hepcidin and ferritin levels was not statistically significant in any of the three groups of thalassemia patients with BTM, BE, or Hb H + AE Bart's (r = -0.141, 0.065 and -0.016, respectively). In conclusion, no statistically significant correlations were observed between serum hepcidin with any variables including serum ferritin, Hb, age, labile plasma iron (LPI), and number of blood transfusion units among the three groups of thalassemia patients. Likely, the regulation of hepcidin in thalassemia patients is affected more by erythropoietic activity than iron storage.
© 2021 The Author(s).

Entities:  

Keywords:  Hb H disease; ferritin; hepcidin; β-thalassemia major; β-thalassemia/Hb E

Mesh:

Substances:

Year:  2021        PMID: 33565577      PMCID: PMC7886874          DOI: 10.1042/BSR20203352

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


  25 in total

1.  Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.

Authors:  Sara Gardenghi; Pedro Ramos; Maria Franca Marongiu; Luca Melchiori; Laura Breda; Ella Guy; Kristen Muirhead; Niva Rao; Cindy N Roy; Nancy C Andrews; Elizabeta Nemeth; Antonia Follenzi; Xiuli An; Narla Mohandas; Yelena Ginzburg; Eliezer A Rachmilewitz; Patricia J Giardina; Robert W Grady; Stefano Rivella
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

Review 2.  Hepcidin and Hfe in iron overload in beta-thalassemia.

Authors:  Sara Gardenghi; Pedro Ramos; Antonia Follenzi; Niva Rao; Eliezer A Rachmilewitz; Patricia J Giardina; Robert W Grady; Stefano Rivella
Journal:  Ann N Y Acad Sci       Date:  2010-08       Impact factor: 5.691

3.  A direct method for quantification of non-transferrin-bound iron.

Authors:  S Singh; R C Hider; J B Porter
Journal:  Anal Biochem       Date:  1990-05-01       Impact factor: 3.365

4.  Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator.

Authors:  Pensri Pootrakul; William Breuer; Matias Sametband; Pornpan Sirankapracha; Chaim Hershko; Z Ioav Cabantchik
Journal:  Blood       Date:  2004-05-20       Impact factor: 22.113

5.  What regulates hepcidin in poly-transfused β-Thalassemia Major: erythroid drive or store drive?

Authors:  Richa Chauhan; Sunita Sharma; Jagdish Chandra
Journal:  Indian J Pathol Microbiol       Date:  2014 Jan-Mar       Impact factor: 0.740

Review 6.  Thalassemia in SouthEast Asia: problems and strategy for prevention and control.

Authors:  S Fucharoen; P Winichagoon
Journal:  Southeast Asian J Trop Med Public Health       Date:  1992-12       Impact factor: 0.267

7.  Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity.

Authors:  C Hershko; G Graham; G W Bates; E A Rachmilewitz
Journal:  Br J Haematol       Date:  1978-10       Impact factor: 6.998

8.  Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome.

Authors:  Esther Zipperer; Jochen G Post; Matthias Herkert; Andrea Kündgen; Frank Fox; Rainer Haas; Norbert Gattermann; Ulrich Germing
Journal:  Ann Hematol       Date:  2013-07-11       Impact factor: 3.673

9.  Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosis.

Authors:  Antonella Roetto; George Papanikolaou; Marianna Politou; Federica Alberti; Domenico Girelli; John Christakis; Dimitris Loukopoulos; Clara Camaschella
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

10.  Hepcidin expression in iron overload diseases is variably modulated by circulating factors.

Authors:  Giulia Ravasi; Sara Pelucchi; Paola Trombini; Raffaella Mariani; Naohisa Tomosugi; Giulia Litta Modignani; Matteo Pozzi; Elizabeth Nemeth; Tomas Ganz; Hisao Hayashi; Donatella Barisani; Alberto Piperno
Journal:  PLoS One       Date:  2012-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.